[{"id":"ad1d963e-b163-427e-be70-2d37437a6605","acronym":"","url":"https://clinicaltrials.gov/study/NCT07471841","created_at":"2026-03-28T01:44:38.203Z","updated_at":"2026-03-28T01:44:38.203Z","phase":"Phase 2","brief_title":"Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax","source_id_and_acronym":"NCT07471841","lead_sponsor":"Timothy Pardee","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Rezlidhia (olutasidenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 05/01/2026","start_date":" 05/01/2026","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2026-03-13"},{"id":"1ab27b74-e0f4-4cec-8b70-3ecfc4fb824b","acronym":"Ven-BUCY","url":"https://clinicaltrials.gov/study/NCT07183878","created_at":"2025-09-27T08:46:54.624Z","updated_at":"2025-09-27T08:46:54.624Z","phase":"","brief_title":"Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)","source_id_and_acronym":"NCT07183878 - Ven-BUCY","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 08/20/2025","start_date":" 08/20/2025","primary_txt":" Primary completion: 08/20/2027","primary_completion_date":" 08/20/2027","study_txt":" Completion: 08/20/2028","study_completion_date":" 08/20/2028","last_update_posted":"2025-09-19"},{"id":"5dbd5ae2-c64a-4324-a92e-acf2900c0634","acronym":"CHANCE","url":"https://clinicaltrials.gov/study/NCT07172204","created_at":"2025-09-20T07:07:45.699Z","updated_at":"2025-09-20T07:07:45.699Z","phase":"Phase 2","brief_title":"Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML","source_id_and_acronym":"NCT07172204 - CHANCE","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 08/15/2025","start_date":" 08/15/2025","primary_txt":" Primary completion: 07/31/2027","primary_completion_date":" 07/31/2027","study_txt":" Completion: 07/31/2029","study_completion_date":" 07/31/2029","last_update_posted":"2025-09-15"},{"id":"17c029cc-5449-4ba9-99f6-13ebaefd3227","acronym":"EVOLVE 1","url":"https://clinicaltrials.gov/study/NCT07075016","created_at":"2025-07-26T13:34:40.222Z","updated_at":"2025-07-26T13:34:40.222Z","phase":"Phase 3","brief_title":"Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy","source_id_and_acronym":"NCT07075016 - EVOLVE 1","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Tibsovo (ivosidenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 227","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-07-20"},{"id":"f73113c5-10a0-4d17-963d-5c3a022450a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT07039877","created_at":"2025-06-28T13:39:04.007Z","updated_at":"2025-06-28T13:39:04.007Z","phase":"Phase 2","brief_title":"Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients","source_id_and_acronym":"NCT07039877","lead_sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • bortezomib • itraconazole"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 01/02/2025","start_date":" 01/02/2025","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-06-26"},{"id":"2698d9cc-7b84-4f76-aa1a-1e9120402516","acronym":"MAVRiC","url":"https://clinicaltrials.gov/study/NCT07024706","created_at":"2025-06-21T13:19:49.221Z","updated_at":"2025-06-21T13:19:49.221Z","phase":"Phase 2","brief_title":"Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab","source_id_and_acronym":"NCT07024706 - MAVRiC","lead_sponsor":"AstraZeneca","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 09/30/2025","start_date":" 09/30/2025","primary_txt":" Primary completion: 11/30/2032","primary_completion_date":" 11/30/2032","study_txt":" Completion: 11/30/2032","study_completion_date":" 11/30/2032","last_update_posted":"2025-06-17"},{"id":"1d2cc1b3-1db7-4ec6-826d-f95392ccf5c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT07012447","created_at":"2025-06-14T13:57:18.760Z","updated_at":"2025-06-14T13:57:18.760Z","phase":"Phase 2","brief_title":"Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations","source_id_and_acronym":"NCT07012447","lead_sponsor":"yuejun Liu","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-06-10"},{"id":"ee6272e6-f952-43d3-a46c-9401133eded9","acronym":"","url":"https://clinicaltrials.gov/study/NCT07007312","created_at":"2025-06-07T14:39:25.624Z","updated_at":"2025-06-07T14:39:25.624Z","phase":"Phase 3","brief_title":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML","source_id_and_acronym":"NCT07007312","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" NPM1","pipe":"","alterations":" ","tags":["NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • daunorubicin • Komzifti (ziftomenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 1300","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 11/01/2031","primary_completion_date":" 11/01/2031","study_txt":" Completion: 11/01/2031","study_completion_date":" 11/01/2031","last_update_posted":"2025-06-05"},{"id":"df8d12a9-7bb0-4607-bc3a-662314ab9674","acronym":"","url":"https://clinicaltrials.gov/study/NCT06993883","created_at":"2025-06-07T14:52:12.102Z","updated_at":"2025-06-07T14:52:12.102Z","phase":"","brief_title":"Use of Venetoclax , AML , Sohag , Egypt","source_id_and_acronym":"NCT06993883","lead_sponsor":"Sohag University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax)"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2025-05-29"},{"id":"5d9596a1-d384-4d3e-99e8-4001de1a4302","acronym":"EVOLVE CLL/SLL","url":"https://clinicaltrials.gov/study/NCT04269902","created_at":"2021-01-18T20:44:42.322Z","updated_at":"2025-02-25T12:27:29.630Z","phase":"Phase 3","brief_title":"Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study","source_id_and_acronym":"NCT04269902 - EVOLVE CLL/SLL","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" TP53 mutation • IGH mutation","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 247","initiation":"Initiation: 03/02/2021","start_date":" 03/02/2021","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2025-02-24"},{"id":"7cd7c85e-4e1b-46fd-8491-96d1bcc8b391","acronym":"IMGN632-0802","url":"https://clinicaltrials.gov/study/NCT04086264","created_at":"2021-01-18T20:00:09.580Z","updated_at":"2025-02-25T12:27:19.012Z","phase":"Phase 1/2","brief_title":"IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia","source_id_and_acronym":"NCT04086264 - IMGN632-0802","lead_sponsor":"AbbVie","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • IL3RA positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • decitabine • pivekimab sunirine (PVEK)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 218","initiation":"Initiation: 11/06/2019","start_date":" 11/06/2019","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-02-24"},{"id":"9e19f934-321f-4e6c-b066-71f0217f0bae","acronym":"","url":"https://clinicaltrials.gov/study/NCT03041688","created_at":"2021-01-18T14:58:33.453Z","updated_at":"2025-02-25T12:26:38.524Z","phase":"Phase 1","brief_title":"Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT03041688","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • CD4","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • TP53 wild-type","tags":["TP53 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • decitabine • navtemadlin (KRT-232)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 02/08/2018","start_date":" 02/08/2018","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-24"},{"id":"68f3baae-dc4f-43a6-80f0-573ab27bebb5","acronym":"ViPOR","url":"https://clinicaltrials.gov/study/NCT03223610","created_at":"2021-01-18T15:54:35.735Z","updated_at":"2025-02-25T13:39:32.188Z","phase":"Phase 1/2","brief_title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma","source_id_and_acronym":"NCT03223610 - ViPOR","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab) • prednisone"],"overall_status":"Recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 02/09/2018","start_date":" 02/09/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-21"},{"id":"a2748e44-3f76-4ef4-9c24-1b7476039a69","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554393","created_at":"2022-09-26T14:56:10.693Z","updated_at":"2025-02-25T13:49:33.606Z","phase":"Phase 2","brief_title":"Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)","source_id_and_acronym":"NCT05554393","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation","tags":["TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 09/13/2024","start_date":" 09/13/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-20"},{"id":"ba5a9900-5311-4370-977a-05b3928feb30","acronym":"","url":"https://clinicaltrials.gov/study/NCT04847453","created_at":"2021-04-19T12:52:34.348Z","updated_at":"2025-02-25T13:49:06.836Z","phase":"Phase 1","brief_title":"Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis","source_id_and_acronym":"NCT04847453","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • MCL1 • BCL2L1 • SDC1 • BAX","pipe":" | ","alterations":" Chr t(11;14)","tags":["BCL2 • MCL1 • BCL2L1 • SDC1 • BAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Ninlaro (ixazomib) • dexamethasone • Hemady (dexamethasone tablets)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 08/03/2022","start_date":" 08/03/2022","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-20"},{"id":"1858e4d9-b3bc-4f84-941b-cd90075ac7b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04708054","created_at":"2021-01-19T20:51:54.886Z","updated_at":"2025-02-25T14:08:06.998Z","phase":"Phase 2","brief_title":"Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS","source_id_and_acronym":"NCT04708054","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • NRAS • DNMT3A • NF1 • RUNX1 • ASXL1 • PTPN1","pipe":" | ","alterations":" TP53 mutation • KRAS mutation • NRAS mutation • RAS mutation","tags":["KRAS • NRAS • DNMT3A • NF1 • RUNX1 • ASXL1 • PTPN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation • NRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cladribine • fludarabine IV • thiotepa • busulfan"],"overall_status":"Recruiting","enrollment":" Enrollment 324","initiation":"Initiation: 10/21/2021","start_date":" 10/21/2021","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-18"},{"id":"da2147db-6d4b-4bfe-ac5e-f6786f79f209","acronym":"","url":"https://clinicaltrials.gov/study/NCT05881265","created_at":"2023-05-31T15:05:36.513Z","updated_at":"2025-02-25T14:17:59.340Z","phase":"Phase 2","brief_title":"Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia","source_id_and_acronym":"NCT05881265","lead_sponsor":"Shanghai Jiao Tong University School of Medicine","biomarkers":" RARA • PML","pipe":"","alterations":" ","tags":["RARA • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Epidaza (chidamide)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/15/2023","start_date":" 05/15/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-18"},{"id":"ae37ad26-112d-406e-b4ec-b9bd80c911c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05292664","created_at":"2022-03-23T13:53:35.750Z","updated_at":"2025-02-25T14:08:44.222Z","phase":"Phase 1","brief_title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","source_id_and_acronym":"NCT05292664","lead_sponsor":"Andrew E. Place, MD","biomarkers":" FLT3 • ABL1 • BCR • BCL2 • KMT2A • IKZF1","pipe":" | ","alterations":" KMT2A rearrangement • ABL1 fusion","tags":["FLT3 • ABL1 • BCR • BCL2 • KMT2A • IKZF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • ABL1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • azacitidine • vincristine • leucovorin calcium • Asparlas (calaspargase pegol-mknl) • dexrazoxane"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 03/29/2023","start_date":" 03/29/2023","primary_txt":" Primary completion: 07/02/2026","primary_completion_date":" 07/02/2026","study_txt":" Completion: 07/02/2028","study_completion_date":" 07/02/2028","last_update_posted":"2025-02-17"},{"id":"2770c644-c8c6-4b54-8f58-0b1d8f8f4795","acronym":"IO-202-CL-001","url":"https://clinicaltrials.gov/study/NCT04372433","created_at":"2023-05-17T22:04:43.287Z","updated_at":"2025-02-25T14:40:35.488Z","phase":"Phase 1","brief_title":"IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML","source_id_and_acronym":"NCT04372433 - IO-202-CL-001","lead_sponsor":"Immune-Onc Therapeutics","biomarkers":" LILRB4","pipe":"","alterations":" ","tags":["LILRB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • IO-202"],"overall_status":"Completed","enrollment":" Enrollment 67","initiation":"Initiation: 09/14/2020","start_date":" 09/14/2020","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2025-02-14"},{"id":"7d78cd12-55c9-4664-9e5c-f58906c32c60","acronym":"","url":"https://clinicaltrials.gov/study/NCT06311227","created_at":"2024-03-15T17:37:14.823Z","updated_at":"2025-02-25T14:42:47.183Z","phase":"Phase 2","brief_title":"Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia","source_id_and_acronym":"NCT06311227","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • TP53","pipe":" | ","alterations":" TP53 mutation","tags":["BRAF • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/15/2025","start_date":" 05/15/2025","primary_txt":" Primary completion: 05/20/2027","primary_completion_date":" 05/20/2027","study_txt":" Completion: 05/20/2027","study_completion_date":" 05/20/2027","last_update_posted":"2025-02-14"},{"id":"a9a958a0-54fc-401f-80e7-fc0331ae93eb","acronym":"MyDRUG","url":"https://clinicaltrials.gov/study/NCT03732703","created_at":"2021-01-18T18:17:27.493Z","updated_at":"2025-02-25T13:18:42.828Z","phase":"Phase 1/2","brief_title":"Myeloma-Developing Regimens Using Genomics (MyDRUG)","source_id_and_acronym":"NCT03732703 - MyDRUG","lead_sponsor":"Multiple Myeloma Research Consortium","biomarkers":" BRAF • SLC1A5","pipe":"","alterations":" ","tags":["BRAF • SLC1A5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • Balversa (erdafitinib) • Xpovio (selinexor) • Ninlaro (ixazomib) • Darzalex (daratumumab) • dexamethasone • Idhifa (enasidenib) • pomalidomide • Blenrep (belantamab mafodotin-blmf) • GDC-0623"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2025-02-14"},{"id":"460f1e61-72a2-48bb-a37c-e804016f6240","acronym":"NCI-2021-06095","url":"https://clinicaltrials.gov/study/NCT05010122","created_at":"2021-08-18T15:53:42.501Z","updated_at":"2025-02-25T15:12:15.219Z","phase":"Phase 1/2","brief_title":"ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT05010122 - NCI-2021-06095","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Xospata (gilteritinib) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 07/08/2021","start_date":" 07/08/2021","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-13"},{"id":"61d56240-acd7-4036-be44-40ad727ab77a","acronym":"A051701","url":"https://clinicaltrials.gov/study/NCT03984448","created_at":"2021-01-18T19:35:47.901Z","updated_at":"2025-02-25T15:11:12.787Z","phase":"Phase 2/3","brief_title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","source_id_and_acronym":"NCT03984448 - A051701","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" BCL2 expression • MYC expression • MYC translocation • MYC negative • BCL2 translocation","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression • MYC translocation • MYC negative • BCL2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 363","initiation":"Initiation: 10/22/2019","start_date":" 10/22/2019","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2025-02-13"},{"id":"814f07a4-6ae3-424e-b8de-ef7b7143e4c7","acronym":"BELLWAVE-010","url":"https://clinicaltrials.gov/study/NCT05947851","created_at":"2023-07-17T14:08:45.600Z","updated_at":"2025-02-25T15:28:11.395Z","phase":"Phase 3","brief_title":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).","source_id_and_acronym":"NCT05947851 - BELLWAVE-010","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" TP53 • BTK • IGH","pipe":" | ","alterations":" TP53 mutation • IGH mutation","tags":["TP53 • BTK • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • nemtabrutinib (MK-1026)"],"overall_status":"Recruiting","enrollment":" Enrollment 720","initiation":"Initiation: 08/08/2023","start_date":" 08/08/2023","primary_txt":" Primary completion: 06/27/2033","primary_completion_date":" 06/27/2033","study_txt":" Completion: 06/27/2033","study_completion_date":" 06/27/2033","last_update_posted":"2025-02-11"}]